Targeting the cell cycle

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 4, 2004, Pages 417-423

  Fischer, Peter M ^a   Glover, David M ^a   Lane, David P ^a  

^a CYCLACEL LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ATM PROTEIN; ATR PROTEIN; CARBAZOLE DERIVATIVE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN D; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; DNA BINDING PROTEIN; FLAVOPIRIDOL; INDISULAM; ISPINESIB; KINESIN; METHYLXANTHINE DERIVATIVE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PENTOXIFYLLINE; POLO LIKE KINASE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; ROSCOVITINE; SB 218078; TRANSCRIPTION FACTOR E2F; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CLINICAL TRIAL; DEREGULATION; DNA REPLICATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; META ANALYSIS; MITOSIS; MITOSIS SPINDLE; NUCLEOTIDE SEQUENCE; TUMOR CELL; TUMOR REGRESSION;

EID: 13344269594     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.11.014     Document Type: Review

References (40)

1. S. Ortega et al. Cyclin D-dependent kinases, INK4 inhibitors and cancer Biochim. Biophys. Acta 1602 2002 73-87
2. L.A. Bell K.M. Ryan Life and death decisions by E2F-1 Cell Death Differ. 11 2004 137-142
3. W.G. Kaelin Jr E2F1 as a target: Promoter-driven suicide and small molecule modulators Cancer Biol. Ther. 2 4 Suppl. 1 2003 34-40
4. Y. Dai S. Grant Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents Curr. Oncol. Rep. 6 2004 123-130
5. P.M. Fischer The use of CDK inhibitors in oncology: A pharmaceutical perspective Cell Cycle 3 2004 742-746
6. J. Booth et al. Inhibition of Cdk4 causes tumor regression Proc. Am. Assoc. Cancer Res. 45 2004 191
7. M. Suganuma et al. Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation Cancer Res. 59 1999 5887-5891
8. Z. Chen et al. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint Mol. Cancer Ther. 2 2003 543-548
9. T. Kawabe G2 checkpoint abrogators as anticancer drugs Mol. Cancer Ther. 3 2004 513-519
10. B-B.S. Zhou J. Bartek Targeting the checkpoint kinases: chemosensitization versus chemoprotection Nat. Rev. Cancer 4 2004 216-225
11. T. Beckers S. Mahboobi Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy Drugs Future 28 2003 767-785
12. T.U. Mayer et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen Science 286 1999 971-974
13. Y. Yan et al. Inhibition of a mitotic motor protein: Where, how, and conformational consequences J. Mol. Biol. 335 2004 547-554
14. F.A. Barr et al. Polo-like kinases and the orchestration of cell division Nat. Rev. Mol. Cell. Biol. 5 2004 429-441
15. P.M. Fischer The design of drug candidate molecules as selective inhibitors of therapeutically relevant kinases Curr. Med. Chem. 11 2004 1563-1583
16. M. Takagi et al. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176 Investig. New Drugs 21 2003 387-399
17. A. Ewart-Toland et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human Nat. Genet. 34 2003 403-412
18. S. Rojanala et al. The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer Mol. Cancer Ther. 3 2004 451-457
19. S.L. Warner et al. Targeting Aurora-2 kinase in cancer Mol. Cancer Ther. 2 2003 589-595
20. S. Hauf et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint J. Cell Biol. 161 2003 281-294
21. L.K. Shawver et al. Smart drugs: Tyrosine kinase inhibitors in cancer therapy Cancer Cell 1 2002 117-123
22. P.M. Fischer A. Gianella-Borradori CDK inhibitors in clinical development for the treatment of cancer Exp. Opin. Investig. Drugs 12 2003 955-970
23. E.A. Nigg Mitotic kinases as regulators of cell division and its checkpoints Nat. Rev. Mol. Cell. Biol. 2 2001 21-32
24. C. Swanton Cell-cycle targeted therapies Lancet Oncol. 5 2004 27-36
25. S.R. Green et al. Identification of pharmacodynamic biomarkers for CYC202 (R-roscovitine), a cyclin dependent kinase inhibitor Proc. Am. Assoc. Cancer Res. 45 2004 846
26. J.D. White et al. A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy Proc. Am. Soc. Clin. Oncol. 23 2004 205
27. G.I. Shapiro Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol Clin. Cancer Res. 10 2004 4270s-4275s
28. S.F. Jones et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors Proc. Am. Soc. Clin. Oncol. 22 2003 199 (Abstract 798)
29. R.N. Misra et al. N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5- [5-(1,1-Dimethylethyl)-2-oxazolyl]methy l]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent J. Med. Chem. 47 2004 1719-1728
30. C. Wheeler et al. Novel approaches in oncology at AstraZeneca EJC Suppl. 1 2003 3-8
31. H.A. Burris et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days Proc. Am. Soc. Clin. Oncol. 23 2004 128
32. B. Spankuch-Schmitt et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells Oncogene 21 2002 3162-3171
33. D.D. Von Hoff et al. A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors Proc. Am. Soc. Clin. Oncol. 23 2004 203
34. E.A. Sausville Aurora kinases dawn as cancer drug targets Nat. Med. 10 2004 234-235
35. E.A. Harrington et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo Nat. Med. 10 2004 262-267
36. Hitoshi, Y. (2004) Aurora kinase inhibitors. Presented at: Gordon Research Conference: Molecular Therapeutics of Cancer, 18-23 July 2004, Colby-Sawyer College, New London, NH, USA (http://www.rigel.com/rigel/oncology_poster)
37. A.A. Mortlock Development of a new series of thiazolo-quinazoline inhibitors targeting Aurora kinase Proc. Am. Assoc. Cancer Res. 45 2004 574
38. R.I. Haddad et al. A phase II study of E7070 in patients with metastatic, recurrent, or refractory head and neck squamous cell carcinoma (HNSCC): Clinical activity and post-treatment modulation of Rb phosphorylation Proc. Am. Soc. Clin. Oncol. 22 2003 200 (Abstract 800)
39. C.T. Supuran Indisulam: An anticancer sulfonamide in clinical development Exp. Opin. Investig. Drugs 12 2003 283-287
40. R. Salazar et al. A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors Clin. Cancer Res. 10 2004 4374-4382